How a 1976 startup turned genetic scissors into a multibillion-dollar pharmaceutical powerhouse
In short: Founded by a venture capitalist and a biochemist, Genentech pioneered recombinant DNA technology to produce human hormones in bacteria. From its first marketed drug to its full acquisition by Roche for nearly $47 billion, the company transformed biotechnology from a laboratory concept into a global industry leader.
Genentech was established in 1976 by Robert A. Swanson and Herbert Boyer, the latter a pioneer in recombinant DNA technology. By 1973, Boyer and Stanley Norman Cohen had demonstrated that restriction enzymes could function as molecular scissors to cut and ligate DNA fragments. This breakthrough enabled Genentech to become the first entity to express a human gene in bacteria, successfully producing somatostatin in 1977, followed by synthetic human insulin in 1978. These early successes laid the foundation for a company that would eventually define the modern biotech landscape.
The company's growth was marked by both scientific innovation and significant legal challenges. Its first marketed drug, Protropin, a growth hormone for treating dwarfism, generated $2 billion in sales but became the subject of a major patent dispute with the University of California, San Francisco. In 1999, Genentech settled the lawsuit for $200 million. Throughout its history, Genentech has maintained a research-driven model, often collaborating with academic institutions and specialized firms to develop therapies for conditions ranging from cancer to asthma. Its portfolio includes notable drugs like Rituxan, Herceptin, and Avastin, the latter of which faced a high-profile FDA approval revocation for breast cancer treatment in 2011.
Today, Genentech operates as a wholly owned subsidiary of Roche, which completed its full acquisition in March 2009 for approximately $46.8 billion. The company continues to evolve its manufacturing and research footprint, recently announcing plans to close its South San Francisco manufacturing site while expanding operations in Oceanside, California. Beyond its scientific output, Genentech has also exerted influence in the policy sphere, utilizing a Political Action Committee to support its interests and engaging in lobbying efforts related to healthcare reform, reflecting its dual role as both a scientific pioneer and a major corporate player in the American healthcare system.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Genentech
To cite this card, link to https://intellectplus.co.uk/app/health-genentech.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health, medicine and disease · More in Health · Latest · A–Z · All topics
